SciSparc SPRC

SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies for central nervous system disorders. The company conducts its pharmaceutical operations primarily through its majority-owned subsidiary NeuroThera, which advances drug candidates targeting conditions such as Tourette syndrome, Alzheimer's disease and agitation, autism spectrum disorder, and status epilepticus. SciSparc’s core technology combines cannabinoids like THC or CBD with its proprietary CannAmide™ formulation, a palmitoylethanolamide-based compound designed to enhance therapeutic effects through a proposed “sparing effect” mechanism.

SciSparc generates revenue through the development and potential commercialization of its pharmaceutical product candidates, including SCI-110, SCI-210, and related intellectual property. The company also derives income from licensing agreements, such as the outlicense of its SCI-160 pain program to Polyrizon, which includes royalty-bearing rights and potential milestone payments. Additionally, SciSparc has historically sold hemp seed oil-based products and other nutraceuticals through its subsidiary SciSparc Nutraceuticals on platforms like Amazon Marketplace, although this business was largely transferred to NeuroThera in October 2025 as part of the NeuroThera Transaction.

The company operates through the following segments:

• Pharmaceutical Development: This segment encompasses the research, preclinical, and clinical development of SciSparc’s cannabinoid-based drug candidates. Key programs include SCI-110 for Tourette syndrome and Alzheimer’s disease and agitation, and SCI-210 for autism spectrum disorder and status epilepticus. These products are formulated with proprietary combinations of THC or CBD and CannAmide™, a trademarked palmitoylethanolamide compound. The segment also includes regulatory advancement activities such as IND clearances, trial initiations, and collaborations with medical institutions like Yale School of Medicine, Hannover Medical School, and Soroka Medical Center.

• Nutraceuticals and Consumer Products: This segment involves the commercialization of hemp-derived wellness products under the Wellution® brand, which includes hemp gummies, oil capsules, gels, creams, detox pills, and antibacterial and anti-aging formulations. Wellution® is a registered trademark in the United States for Class 003 and Class 005 goods. Products are manufactured in the United States and have been distributed through online retailers, including Amazon Marketplace, under licensing and distribution agreements with SciSparc Nutraceuticals.

SciSparc holds a specialized position in the pharmaceutical industry as a developer of cannabinoid-based combination therapies targeting neuropsychiatric and neurological disorders with high unmet medical need. Its competitive advantage lies in its proprietary CannAmide™ platform, which is designed to enhance the efficacy and safety of cannabinoids like THC and CBD through modulation of the endocannabinoid system. The company differentiates itself from larger competitors such as GW Pharmaceuticals (maker of Epidiolex and Sativex) and AbbVie (marketer of Marinol) by focusing on novel combination therapies rather than single-agent cannabinoid products. SciSparc’s intellectual property portfolio, including multiple granted patents and pending applications covering cannabinoid-PEA combinations, further supports its market positioning and creates potential barriers to entry.

SciSparc serves patients and healthcare providers seeking treatment for central nervous system disorders, including individuals with Tourette syndrome, Alzheimer’s disease-related agitation, autism spectrum disorder, and status epilepticus. The company collaborates with clinical trial sites such as Sourasky Medical Center, Hannover Medical School, and the Israeli Medical Center for Alzheimer’s to evaluate its product candidates in patient populations. Its nutraceutical division historically sold directly to consumers through e-commerce channels, particularly Amazon Marketplace in Canada, under exclusive licensing arrangements.